J Genet Mol Res:乙肝HBeAg和Anti-HBeAb同时阳性可能吗 ?

2017-10-13 佚名i 检验医学网

关于乙肝表面抗原HBsAg与乙肝表面抗体HBsAb同时阳性,有很多文章做了解读,相信检验同仁都已经了解了。我们再简单回顾下HBsAg和HBsAb同时阳性的5种原因:


关于乙肝表面抗原HBsAg与乙肝表面抗体HBsAb同时阳性,有很多文章做了解读,相信检验同仁都已经了解了。我们再简单回顾下HBsAg和HBsAb同时阳性的5种原因:

(1) 与研究方法,试剂灵敏性等相关。对上万例乙肝五项进行检测方法学比较得出,若选用酶联免疫吸附试验(ELISA)定性检测方法来说,若出现双阳性,假阳性的可能性比较大。这与ELISA方法的灵敏性和特异性有关。ELISA相对于CMIA化学发光微粒子方法来说,实验灵敏性低,特异性差,容易受到干扰(洗板,污染等)。ELISA和CMIA结果 的相关性比较低0.05,尤其HBSAg的低值部分,ELISA容易出现假阳性或假阴性,可以用CMIA方法进行复检。

(2)不同亚型的HBV重叠感染导致患者体内针对某一乙肝表面抗原亚型产生的乙肝抗体,不能中和由另一乙肝表面抗原亚型的感染

(3)由于抗乙肝病毒药物或疫苗接种 、免疫球蛋白的广泛应用,使乙肝病毒S基因发生变异。导致HBsAg和HBsAb亲和性降低而使其无法清除抗原。在免疫选择压力下, 突变病毒株成为优势株, 针对野生株的抗体和突变株的抗原共存, 而该抗体无法清除突变的抗原。

(4)患者处于HBV感染的恢复期,患者体内存在HBsAg-Anti-HBs的免疫复合物;钱福初等人结合临床发现急性乙型肝炎患者出现抗原抗体共存, 往往是疾病处于恢复期, 此时抗体已经出现而抗原还未消失, 进一步随访显示抗原转阴而抗体持续阳性。而对13 例慢性乙型肝炎患者进行动态观测乙肝标志物发现其抗原抗体始终呈阳性, 提示抗体的出现并不能完全清除表面抗原。长期同时阳性的患者会增加慢性乙型肝炎病毒感染发展肝癌的风险。

(5)存在HBV的突变,常见于新生儿母婴感染以及肝移植的患者;

HBsAg和HBsAb同时阳性出现的几率占所有HBV慢性感染人群的3-5%左右。所以实验室人员检测出HBsAg和Anti-HBs同时阳性是存在共性的。

乙肝E抗原和E抗体同时阳性呢,有可能吗?
可能!

通常认为HBeAg阳性一般反映HBV复制活跃,传染性较强。HBeAb抗体一般在HBeAg由阳性转为阴性后产生,表明部分病毒被清除,传染性降低,乙肝病情有所缓解。这个过程称之为HBeAg的血清转换(seroconversion),也是国内指南推荐的慢乙肝 “满意治疗终点” 的主要标志之一。在这个时期,通常两者浓度都很低,一般都不容易测出,多篇文献显示占慢性乙肝CHB患者的0.2%-0.6%,也有报道高达10.4%。

同时阳性的可能原因有:

1.“血清转换” (seroconversion)处在免疫应答过程阶段。在HBeAg出现后,其可刺激机体免疫应答产生Anti-HBe。当Anti-HBe开始出现,但HBeAg仍有较高浓度时,二者即可同时出现。随着Anti-HBe浓度的持续增加,HBeAg逐步被消除。当HBeAg和Anti-HBe同时阳性时,常出现两者接近于截断值(Cutoff值)的情况。这是机体在对乙肝病毒免疫应答过程当中可能出现的一个阶段,此期间肝脏病变累积较重。随着干扰素及类核苷药物的使用,增加了因“血清转换”出现e抗原抗体同时阳性的概率。

2.试剂的检测敏感度的提高。在ELISA检测中,可能会由于检测灵敏度不够高,常会出现HBeAg和Anti-HBe阴性而HBV-DNA高水平的患者病例。随着化学发光技术的广泛应用,比ELISA具有更高灵敏度, 可在低浓度下检测出HBeAg和Anti-HBe,可以更灵敏地识别早期HBV亚型的感染或HBsAg向HBsAb的早期转变。面对这种现象值得注意的是:1)需排除HBeAg和Anti-HBe的假阳性,最好进行中和试验;2)动态观察患者血清HBeAg和Anti-HBe的消长曲线,甚至有可能出现反复的情况,利用好这些信息可更早期发现患者出现e抗原抗体的血清转换,为临床疗效评估提供指导。

3.考虑“假阳性”的可能。e抗原抗体同时阳性需要考虑试剂及操作过程所造成的假阳性。邱振华等人对53例ELISA初检为e抗原抗体双阳的标本,用HBeAg中和试验后发现仅19例是真正同时阳性。造成假阳的原因可能有试剂的一步法勾状效应,洗板不干净,离心不完全,纤维蛋白或夹杂RBC,等原因所致。故建议采用二步法,且需遵照试剂说明书进行规范操作。如若遇到需要复检、冻融或有颗粒物标本,标本离心>10000RCF(相对离心力),10分钟后再进行检测,有条件应做中和试验,以确保结果的可靠性。

4.抗乙肝病毒治疗引起病毒基因变异。张键等人研究发现80%左右的e抗原抗体同时阳性的患者感染了基本核心启动(BCP)区T1762/A1764和/或前C区A1896终止密码子的变异株。这些变异是抗病毒治疗是否应答的决定因素之一。HBeAg/抗-HBe 双阳性越来越多出现于抗病毒治疗HBeAg不断降低的过程中。值得注意的是HBeAg和Anti-HBeAb同时阳性的抗病毒治疗患者其血清指标可能会出现反复,HBV复制仍在中等水平,且常伴有肝功能损伤。

目前,引起血清标志物HBeAg和Anti-HBeAb同时阳性的特殊模式的机制尚在不断研究之中。如果患者出现乙肝病毒血清学检验出不常见的检查结果, 首先应排除检测方法造成的假阴性或假阳性;结合患者肝功能指标及病毒DNA复制情况、既往病史和临床症状、展开针对性分析,确保能够顺利获取有效的检验结果。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1733928, encodeId=cde21e33928a0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Apr 21 01:50:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048916, encodeId=4e902048916f6, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 23 10:50:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686146, encodeId=f6d61686146c3, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Sep 15 16:50:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368950, encodeId=4d67136895048, content=<a href='/topic/show?id=859f850513' target=_blank style='color:#2F92EE;'>#HBeAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8505, encryptionId=859f850513, topicName=HBeAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Sun Oct 15 11:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2018-04-21 canlab
  2. [GetPortalCommentsPageByObjectIdResponse(id=1733928, encodeId=cde21e33928a0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Apr 21 01:50:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048916, encodeId=4e902048916f6, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 23 10:50:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686146, encodeId=f6d61686146c3, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Sep 15 16:50:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368950, encodeId=4d67136895048, content=<a href='/topic/show?id=859f850513' target=_blank style='color:#2F92EE;'>#HBeAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8505, encryptionId=859f850513, topicName=HBeAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Sun Oct 15 11:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2018-06-23 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1733928, encodeId=cde21e33928a0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Apr 21 01:50:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048916, encodeId=4e902048916f6, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 23 10:50:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686146, encodeId=f6d61686146c3, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Sep 15 16:50:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368950, encodeId=4d67136895048, content=<a href='/topic/show?id=859f850513' target=_blank style='color:#2F92EE;'>#HBeAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8505, encryptionId=859f850513, topicName=HBeAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Sun Oct 15 11:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1733928, encodeId=cde21e33928a0, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sat Apr 21 01:50:00 CST 2018, time=2018-04-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048916, encodeId=4e902048916f6, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sat Jun 23 10:50:00 CST 2018, time=2018-06-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1686146, encodeId=f6d61686146c3, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Sat Sep 15 16:50:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1368950, encodeId=4d67136895048, content=<a href='/topic/show?id=859f850513' target=_blank style='color:#2F92EE;'>#HBeAg#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8505, encryptionId=859f850513, topicName=HBeAg)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0357291, createdName=xiaoshitou, createdTime=Sun Oct 15 11:50:00 CST 2017, time=2017-10-15, status=1, ipAttribution=)]
    2017-10-15 xiaoshitou